Schrader J, Köstering H, Kramer P, Scheler F
Dtsch Med Wochenschr. 1982 Dec 3;107(48):1847-50. doi: 10.1055/s-2008-1070219.
Haemodialysis had become impossible or possible only using high doses of heparin in 20 patients with dialysis-dependent renal insufficiency due to lowering of antithrombin III (AT III). In order to assess the value of AT III substitution for effective heparin treatment and concomitant diminution of the danger of haemorrhage AT III substitution was done in these patients. Six patients. Six patients with acute renal failure and disseminated intravascular coagulation were able to undergo dialysis using only 750-1000 IU heparin/h after normalisation of AT III without complications. In 3 patients thrombosing of the extracorporeal system had occurred despite increasing doses of heparin; only after 1500 U AT III subsequent haemodialysis could be performed without thromboses. Dialysis was performed with continuous substitution of the AT III-heparin-complex in 6 patients prone to haemorrhage. 250-500 U of AT III-heparin-complex were sufficient and proved as safe and well manageable possibility of minimal anticoagulation. In 5 patients repeated thrombosing of the haemofilter per day had occurred during continuous arteriovenous haemofiltration. After AT III administration haemofilters could be left in situ for 18-46 hours.
由于抗凝血酶III(AT III)水平降低,20例依赖透析的肾功能不全患者进行血液透析变得不可能,或仅在使用高剂量肝素时才有可能。为了评估AT III替代对于有效肝素治疗及同时降低出血风险的价值,对这些患者进行了AT III替代治疗。6例急性肾衰竭合并弥散性血管内凝血的患者在AT III恢复正常后,仅使用750 - 1000 IU肝素/小时就能进行透析,且无并发症。3例患者尽管增加了肝素剂量,体外循环系统仍发生血栓形成;仅在给予1500 U AT III后,后续血液透析才能无血栓进行。对6例有出血倾向的患者进行血液透析时持续补充AT III - 肝素复合物。250 - 500 U的AT III - 肝素复合物就足够了,被证明是一种安全且易于管理的最低抗凝可能性。5例患者在持续动静脉血液滤过期间,血液滤过器每天反复发生血栓形成。给予AT III后,血液滤过器可原位保留18 - 46小时。